The American Society of Clinical Oncology (ASCO) today issued a set of recommendations for overcoming financial barriers to patient participation in cancer clinical trials. ASCO’s policy statement, “Addressing Financial Barriers to Patient Participation in Clinical Trials,” stresses the importance of increasing participation in clinical research, especially for patients from particular ethnic/racial, geographic, age, socioeconomic, and other underserved demographic subgroups.
ALEXANDRIA, Va. — The number of international practices certified in delivering high-quality cancer care based on rigorous standards established by the American Society of Clinical Oncology (ASCO) is increasing. The Medisprof Cancer Center in Romania joins six other practices in Brazil, Greece, and Spain in achieving ASCO’s Quality Oncology Practice Initiative (QOPI®) Certification.
Alexandria, Va. – The American Society of Clinical Oncology (ASCO) warns that certain provisions of the 2019 Medicare Physician Fee Schedule (MPFS) proposed rule will undermine access to cancer care for Medicare beneficiaries through a combination of payment reductions under the MPFS. In a detailed comment letter to the Centers for Medicare & Medicaid Services (CMS), ASCO fully outlines its concerns with the proposal and recommends specific steps be taken to ensure changes proposed in the rule do not endanger Medicare beneficiary access to cancer care.
Alexandria, Va. — CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO®), has announced that Stanford Health Care has signed an agreement to participate in the CancerLinQ® platform. Stanford Health Care includes Stanford Cancer Institute which is designated as a Comprehensive Cancer Center by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH).
Senator John McCain will lie in state in the U.S. Capitol Building today. The following ASCO statement pays tribute to his life-long service to our country.
Alexandria, Va. —In a new position statement, the American Society of Clinical Oncology (ASCO) warns that some of the practices of pharmacy benefit manager (PBM) companies use could hinder patient access to timely, high-quality cancer care. ASCO describes a range of PBM practices that, while they may be intended to help control costs in cancer care, might compromise physicians’ ability to provide the right treatment at the right time for people with cancer.
ALEXANDRIA, Va. – CancerLinQ LLC announced today that Integra Connect’s EHR Solution for Oncology has been recognized as the first CancerLinQ® Certified Electronic Health Record (EHR) System. CancerLinQ LLC is a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO) that oversees the development and operation of CancerLinQ®, a health information technology platform working to improve quality and value of care for all patients by connecting cancer care team members, researchers, and sponsors with real-world cancer data. In addition, CancerLinQ and Integra Connect have entered into an agreement to collaborate on products and services geared toward improving the quality of cancer care and the access of the CancerLinQ® platform to oncology practices.
Alexandria, Va. — CancerLinQ LLC, a wholly-owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO), has brought on technology collaborators Concerto HealthAI and Tempus to accelerate its joint research effort with the Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) aimed at understanding the real-world use, tolerability, and effectiveness of immune checkpoint inhibitors. Concerto HealthAI and Tempus have begun to assist in the analysis of a de-identified data set that CancerLinQ has provided to the FDA, representing more than 10,000 patients who have been treated with immune checkpoint inhibitors for both approved and unapproved indications.
Alexandria, VA – Advanced practice providers (APPs) have increasingly become integral members of the oncology care delivery team, according to the first large-scale study of nurse practitioners (NPs) and physician assistants (PAs) in oncology published today in the Journal of Oncology Practice. The “Understanding the Role of Advanced Practice Providers in the U.S.” study was conducted as a collaboration of the American Society of Clinical Oncology (ASCO), the American Academy of PAs (AAPA), the Association of Physician Assistants in Oncology (APAO), the Advanced Practitioner Society for Hematology and Oncology (APSHO), and the Oncology Nursing Society (ONS).
Alexandria, Va. – The American Society of Clinical Oncology (ASCO) warns that Medicaid work requirements may hinder patients’ access to essential cancer care and reduce the already limited time physicians are able to spend with their patients. In a new position statement released today, ASCO also recommends that federal and state policymakers take specific steps to ensure that new Medicaid requirements will not harm patients with cancer.
ALEXANDRIA, Va. — Cory Wiegert has been named Chief Executive Officer (CEO) of CancerLinQ LLC, a wholly owned non-profit subsidiary of the American Society of Clinical Oncology (ASCO). Mr. Wiegert, a proven expert in building and successfully launching innovative technology solutions, will begin his new role on August 13, 2018, overseeing the continued expansion and implementation of the CancerLinQ® platform.
WASHINGTON, D.C. -- The American Society of Clinical Oncology, Inc. (ASCO®) and Friends of Cancer Research (Friends) have submitted to the Food and Drug Administration (FDA) recommended language for five guidance documents on ways to broaden eligibility criteria for cancer clinical trials. The recommendations are part of an ASCO and Friends collaboration to broaden eligibility for participating in clinical trials by addressing five specific areas: minimum age requirements for trial enrollment, HIV/AIDS status, brain metastases, organ dysfunction, and prior and concurrent malignancies.
ASCO strongly opposes the Centers for Medicare & Medicaid Services (CMS) decision to allow Medicare Advantage plans to employ step therapy across physician-administered and self-administered drugs under Medicare Part B and Part D.
A new “frailty index” predicts overall survival for patients newly diagnosed with multiple myeloma, according to a study published today in JCO Clinical Cancer Informatics (JCO CCI). This tool is important because frailty is a critical factor in treatment decision-making for many patients with multiple myeloma, as the cancer most commonly arises among older adults. According to the authors, this tool is the first of its kind to assess frailty based on the accumulation of aging-associated diseases and disabilities—or biological age—rather than chronological age alone to predict overall survival in multiple myeloma.
ASCO strongly opposes provisions in the 2019 Medicare Physician Fee Schedule (MPFS) proposed rule that could significantly cut cancer care resources that are needed to provide high-quality care to individuals with cancer.